Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Blood (2015) 126 (23): 5322.

https://doi.org/10.1182/blood.V126.23.5322.5322

Published: 2015

Journal Articles

The Cardiovascular Impact of Carfilzomib in Multiple Myeloma

Allison C. Rosenthal, DO, Jennifer Luthi, RN BSN OCN, Marek Belohlavek, MDPhD, Farouk Mookadam, MB ChB, Angela Mayo, PA, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Craig B. Reeder, MD, Joseph R. Mikhael, MD, Keith Stewart, MBA, MB, CHB

Blood (2014) 124 (21): 4748.

https://doi.org/10.1182/blood.V124.21.4748.4748

Published: 2014

Journal Articles

A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort

Joseph R. Mikhael, MD, Craig B. Reeder, MD, Edward N. Libby, III, MD, Luciano J Costa, MD, PhD, Peter Leif Bergsagel, MD, Francis Buadi, MD, Angela Mayo, PA/NP, Katherine Gano, Cassandra Wolf, Amylou Constance Dueck, PhD, A. Keith Stewart, MBA, MB, CHB

Blood (2013) 122 (21): 3179.

https://doi.org/10.1182/blood.V122.21.3179.3179

Published: 2013

Journal Articles

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Erik H van Beers, PhD, Martin H. Van Vliet, PhD, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Shaji K Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Sagar Lonial, M.D., Donna E Reece, MD, FRCPC, Paul G. Richardson, MD, David S Siegel, MD, PhD, Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, MSC, FRCPC, Ravi Vij, MD, Todd M. Zimmerman, MD, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 1854.

https://doi.org/10.1182/blood.V122.21.1854.1854

Published: 2013

Journal Articles

A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma

Blood (2013) 122 (21): 1940.

https://doi.org/10.1182/blood.V122.21.1940.1940

Published: 2013

Journal Articles

Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma : Preliminary Results In 77 p53 Deleted Patients

K. Martin Kortuem, MD, Christian Langer, MD, Esteban Braggio, Ph.D., Scott Van Wier, Jan Egan, PhD, Laura Bruins, Jessica Schmidt, Lars Bullinger, MD, PhD, Miriam Kull, MD, Stefan Knop, MD, Hermann Einsele, MD, A. Keith Stewart, MBA, MB, CHB

Blood (2013) 122 (21): 4449.

https://doi.org/10.1182/blood.V122.21.4449.4449

Published: 2013

Journal Articles

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Blood (2013) 122 (21): 4352.

https://doi.org/10.1182/blood.V122.21.4352.4352

Published: 2013

Journal Articles

The Genomic Landscape Of Primary Central Nervous System Lymphomas

Esteban Braggio, Ph.D., Brian Patrick O'Neill, MD, Scott Van Wier, Juhi Ojha, PhD, Jackline ayres-Silva, Riccardo Valdez, MD, Jan Egan, PhD, Ellen McPhail, MD, Maria Beatriz Lopes, David Schiff, MD, Raoul Tibes, MD, Keith Stewart, MBA, MB, CHB, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 504.

https://doi.org/10.1182/blood.V122.21.504.504

Published: 2013

Journal Articles

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, Andrew Spencer, MD, Heather J. Sutherland, MD, PhD, FRCPC, Michael E O'Dwyer, MD, FRCPI, FRCPath, Shang-Yi Huang, MD, PhD, Keith Stewart, MBA, MB, CHB, Ajai Chari, MD, Michael Rosenzwieg, MD, Ajay K. Nooka, MD, MPH, Cara A Rosenbaum, MD, Craig C Hofmeister, MD, Deborah A Smith, PharmD, Joyce M Antal, Ademi Santiago-Walker, Jennifer Gauvin, Joanna B Opalinska, Suzanne Trudel, MD

Blood (2013) 122 (21): 283.

https://doi.org/10.1182/blood.V122.21.283.283

Published: 2013

Journal Articles

PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma

Sinto Sebastian, Ph.D., Marta Chesi, PhD, Esteban Braggio, Ph.D., Leif Bergsagel, MD, Keith Stewart, MBA, MB, CHB, Gregory Ahmann, BS, Rafael Fonseca, MD

Blood (2012) 120 (21): 1846.

https://doi.org/10.1182/blood.V120.21.1846.1846

Published: 2012

Journal Articles

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

Yuan Xiao Zhu, Ph.D., Chang-Xin Shi, Ph.D., Laura Bruins, Klaus Martin Kortuem, MD, Jessica Schmidt, Xiu-Bao Chang, Ph.D., Esteban Braggio, Ph.D., Leif Bergsagel, M.D., Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 1807.

https://doi.org/10.1182/blood.V120.21.1807.1807

Published: 2012

Journal Articles

GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

Suzanne Trudel, MD, Sam Scanga, PhD, Fabrizio G Mastronardi, PhD, Ellen Nong Wei, MSc, Frank Mercurio, PhD, Antonia Lopez-Girona, PhD, Svetlana Gaidarova, MS, David R. Webb, PhD, Christine Chen, MD, Keith Stewart, MBA, MB, CHB, Armen S Manoukian, PhD

Blood (2012) 120 (21): 1793.

https://doi.org/10.1182/blood.V120.21.1793.1793

Published: 2012

Journal Articles

Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma

Joseph R. Mikhael, MD, Craig B. Reeder, MD, Edward N. Libby, III, MD, Luciano J. Costa, MD, PhD, P. Leif Bergsagel, M.D., Francis Buadi, MD, Angela Mayo, PA, Katherine Gano, Cassandra Wolf, Amylou Constance Dueck, PhD, A. Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 445.

https://doi.org/10.1182/blood.V120.21.445.445

Published: 2012

Journal Articles

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Shaji K. Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Mehdi Hamadani, MD, A. Keith Stewart, MBA, MB, CHB, Vivek Roy, M.D., Parameswaran Hari, MBBS, MD, MRCP, Robert Vescio, MD, Deborah Berg, RN, MSN, Jianchang Lin, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 332.

https://doi.org/10.1182/blood.V120.21.332.332

Published: 2012

Journal Articles

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, MD, Betsy R. LaPlant, Wee Joo Chng, MD, PhD, Jeffrey A. Zonder, MD, Natalie Callander, MD, Vivek Roy, M.D., Briant Furth, Charles Erlichman, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 76.

https://doi.org/10.1182/blood.V120.21.76.76

Published: 2012

Journal Articles

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

Jan Egan, PhD, Klaus Martin Kortuem, MD, Chang-Xin Shi, PhD, Jessica Schmidt, David Craig, PhD, John Carpten, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 3968.

https://doi.org/10.1182/blood.V120.21.3968.3968

Published: 2012

Journal Articles

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Christof Scheid, MD, PhD, Donna Reece, Meral Beksac, MD, Andrew Spencer, MD, Natalie Callander, MD, Pieter Sonneveld, MD, Ghulam Kalimi, PhD, Can Cai, Michael Shi, MD, PhD, Jeffrey W. Scott, A. Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4055.

https://doi.org/10.1182/blood.V120.21.4055.4055

Published: 2012

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4029.

https://doi.org/10.1182/blood.V120.21.4029.4029

Published: 2012

Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4034.

https://doi.org/10.1182/blood.V120.21.4034.4034

Published: 2012

Journal Articles

Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,

Blood (2011) 118 (21): 3963.

https://doi.org/10.1182/blood.V118.21.3963.3963

Published: 2011

NARROW

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

The Cardiovascular Impact of Carfilzomib in Multiple Myeloma

A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma

Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma : Preliminary Results In 77 p53 Deleted Patients

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

The Genomic Landscape Of Primary Central Nervous System Lymphomas

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only